Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer

Cancer Research

Volumn 68, Issue 21, 2008, Pages 9024-9032

  Aziz, Moammir H ^a   Dreckschmidt, Nancy E ^a   Verma, Ajit K ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; BIOLOGICAL MARKER; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PLUMBAGIN; PLUMBAGO ZEYLANICA EXTRACT; PROTEIN BCL XL; PROTEIN KINASE C EPSILON; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER INVASION; CELL IMMORTALIZATION; CELL STRAIN RWPE 1; CONTROLLED STUDY; DNA BINDING; DRUG ISOLATION; DRUG MECHANISM; DRUG TARGETING; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CELL DIVISION; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; NAPHTHOQUINONES; NEOPLASM INVASIVENESS; PLANTS, MEDICINAL; PROSTATIC NEOPLASMS;

EID: 55349147671     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2494     Document Type: Article

References (50)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2. Androgen-receptor cofactors and bypass pathways. BJU Int 2005;95:1327-35.
3. Zhou J, Scholes J, Hsieh JT. Signal transduction targets in androgen-independent prostate cancer. Cancer Metastasis Rev 2001;20:351-62.
4. Silvestris N, Leone B, Numico G, et al. Present status and perspectives in the treatment of hormone-refractory prostate cancer. Oncology 2005;69:273-82.
5. Chau CH, Figg WD. Molecular and phenotypic heterogeneity of metastatic prostate cancer. Cancer Biol Ther 2005;4:166-7.
6. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41:858-87.
7. Sandur SK, Ichikawa H, Sethi G, et al. Plumbagin (5-hydroxy-2-methyl-1,4- naphthoquinone) suppresses NF-κB activation and NF-κB-regulated gene products through modulation of p65 and IκBα kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J Biol Chem 2006;281:17023-33.
8. Sugie S, Okamoto K, Rahman KM, et al. Inhibitory effects of plumbagin and juglone on azoxymethane-induced intestinal carcinogenesis in rats. Cancer Lett 1998;127:177-83.
9. 2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther 2006;5:3209-21.
10. 2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther 2006;318:484-94.
11. Wang CC, Chiang YM, Sung SC, et al. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett 2008;259:82-98.
12. Powolny AA, Singh SV. Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species. Cancer Lett 2008;259:82-2008.
13. Rajesh D, Schell K, Verma AK. Ras mutation, irrespective of cell type and p53 status, determines a cell's destiny to undergo apoptosis by okadaic acid, an inhibitor of protein phosphatase 1 and 2A. Mol Pharmacol 1999;56:515-25.
14. Aziz MH, Manoharan HT, Church DR, et al. Protein kinase Cε interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. Cancer Res 2007;67:8828-38.
15. Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 2008;27:41-55.
16. Keller ET, Dai J, Escara-Wilke J, et al. New trends in the treatment of bone metastasis. J Cell Biochem 2007;102:1095-102.
17. Kingsley LA, Fournier PG, Chirgwin JM, et al. Molecular biology of bone metastasis. Mol Cancer Ther 2007;6:2609-17.
18. Valdespino V, Tsagozis P, Pisa P. Current perspectives in the treatment of advanced prostate cancer. Med Oncol 2007;24:273-86.
19. Gupta S. Prostate cancer chemoprevention: current status and future prospects. Toxicol Appl Pharmacol 2007;224:369-76.
20. Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise [review]. Int J Oncol 2007;30:233-45.
21. Adhami VM, Mukhtar H. Polyphenols from green tea and pomegranate for prevention of prostate cancer. Free Radic Res 2006;40:1095-104.
22. Bemis DL, Katz AE, Buttyan R. Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opin Investig Drugs 2006;15:1191-200.
23. Srinivas G, Annab LA, Gopinath G, et al. Antisense blocking of BRCA1 enhances sensitivity to plumbagin but not tamoxifen in BG-1 ovarian cancer cells. Mol Carcinog 2004;39:15-25.
24. Srinivas P, Gopinath G, Banerji A, et al. Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells. Mol Carcinog 2004;40:201-11.
25. Kawiak A, Piosik J, Stasilojc G, et al. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II. Toxicol Appl Pharmacol 2007;223:267-76.
26. Shankar S, Ganapathy S, Chen Q, et al. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer 2008;7:16.
27. Kong D, Li Y, Wang Z, et al. Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-κB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007;67:3310-9.
28. Adhami VM, Ahmad N, Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J Nutr 2003;133:2417-24S.
29. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007;7:281-94.
30. Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J 1998;332:281-92.
31. Newton AC. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 2001;101:2353-64.
32. Mochly-Rosen D, Kauvar LM. Modulating protein kinase C signal transduction. Adv Pharmacol 1998;44:91-145.
33. Basu A, Sivaprasad U. Protein kinase Cε makes the life and death decision. Cell Signal 2007;19:1633-42.
34. Cornford P, Evans J, Dodson A, et al. Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol 1999;154:137-44.
35. Wu D, Foreman TL, Gregory CW, et al. Protein kinase Cε has the potential to advance the recurrence of human prostate cancer. Cancer Res 2002;62:2423-9.
36. Wu D, Thakore CU, Wescott GG, et al. Integrin signaling links protein kinase Cε to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene 2004;23:8659-72.
37. Wu D, Terrian DM. Regulation of caveolin-1 expression and secretion by a protein kinase Cε signaling pathway in human prostate cancer cells. J Biol Chem 2002;277:40449-55.
38. Huang HF, Murphy TF, Shu P, et al. Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells. Mol Cancer 2005;4:2.
39. Alvarez JV, Febbo PG, Ramaswamy S, et al. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res 2005;65:5054-62.
40. Burke WM, Jin X, Lin HJ, et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001;20:7925-34.
41. Ni Z, Lou W, Leman ES, et al. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res 2000;60:1225-8.
42. Fernandes A, Hamburger AW, Gerwin BI. ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int J Cancer 1999;83:564-70.
43. Kobielak A, Fuchs E. Links between α-catenin, NF-κB, and squamous cell carcinoma in skin. Proc Natl Acad Sci U S A 2006;103:2322-7.
44. Levy DE, Darnell JE, Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002;3:651-62.
45. Chan KS, Sano S, Kiguchi K, et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 2004;114:720-8.
46. McJilton MA, Van Sikes C, Wescott GG, et al. Protein kinase Cε interacts with Bax and promotes survival of human prostate cancer cells. Oncogene 2003;22:7958-68.
47. Suzuki H, Ueda T, Ichikawa T, et al. Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 2003;10:209-16.
48. Danielpour D. Functions and regulation of transforming growth factor-β (TGF-β) in the prostate. Eur J Cancer 2005;41:846-57.
49. Craft N, Shostak Y, Carey M, et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-5.
50. Chen J, Deng F, Singh SV, et al. Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCε/PKD3 pathway downstream of Akt and ERK 1/2. Cancer Res 2008;68:3844-53.